Literature DB >> 17300766

Role of kappa and delta opioid receptors in mediating morphine-induced antinociception in morphine-tolerant infant rats.

Dawn C Stoller1, Laura J Sim-Selley, Forrest L Smith.   

Abstract

We have previously noted that the antinociceptive efficacy of morphine was significantly decreased in rat pups chronically infused with morphine from implanted osmotic minipumps. In this study, morphine was fully efficacious (i.e., 100% maximum possible effect, %MPE) in the 52 degrees C tail-immersion test after a 72-h infusion from implanted saline-filled osmotic minipumps. However, administration of up to 1000 mg/kg, s.c. morphine failed to elicit greater than a 27% MPE in rats infused with morphine at 2 mg/kg/h. Morphine was more efficacious when the water bath temperature was decreased to 49 degrees C. Experiments were conducted to determine the mechanisms whereby chronic morphine administration leads to a decrease in antinociceptive efficacy. The kappa-opioid antagonist nor-binalorphimine completely blocked the antinociceptive effects of morphine in morphine-infused rat pups. The kappa agonist U50,488 elicited antinociception; however, the requirement to use higher doses in morphine- than saline-infused rats indicates that kappa cross-tolerance was present. Thus, in tolerant rats the antinociceptive effects of high doses of morphine appear to be mediated through kappa-opioid receptors. The delta-opioid antagonist naltrindole was inactive in both treatment groups. DAMGO-stimulated [(35)S]GTPgammaS and [(3)H]naloxone binding reveals that the anatomical distribution of the mu-opioid receptor was consistent with that of the adult rat brain. In adult rats, the mu-opioid receptor is desensitized during morphine tolerance. However, desensitization was not evident in P17 rats based on the lack of significant decreases in [(35)S]GTPgammaS binding. Furthermore, [(3)H]naloxone binding indicated a lack of mu receptor downregulation in morphine-tolerant rat pups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17300766      PMCID: PMC3159155          DOI: 10.1016/j.brainres.2007.01.028

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  38 in total

1.  Morphine-induced downregulation of mu-opioid receptors and peptide synthesis in neonatal rat brain.

Authors:  A Tempel; K Espinoza
Journal:  Ann N Y Acad Sci       Date:  1992-06-28       Impact factor: 5.691

2.  mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.

Authors:  K Stafford; A B Gomes; J Shen; B C Yoburn
Journal:  Pharmacol Biochem Behav       Date:  2001 May-Jun       Impact factor: 3.533

3.  Chronic morphine increases mu-opiate receptor binding in rat brain: a quantitative autoradiographic study.

Authors:  L S Brady; M Herkenham; J B Long; R B Rothman
Journal:  Brain Res       Date:  1989-01-16       Impact factor: 3.252

4.  Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.

Authors:  C A Paronis; S G Holtzman
Journal:  J Pharmacol Exp Ther       Date:  1992-07       Impact factor: 4.030

5.  Noxious thermal and chemical stimulation induce increases in 3H-phorbol 12,13-dibutyrate binding in spinal cord dorsal horn as well as persistent pain and hyperalgesia, which is reduced by inhibition of protein kinase C.

Authors:  K Yashpal; G M Pitcher; A Parent; R Quirion; T J Coderre
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

6.  Chronic morphine induces tolerance and desensitization of mu-opioid receptor but not down-regulation in rabbit.

Authors:  J Polastron; J C Meunier; P Jauzac
Journal:  Eur J Pharmacol       Date:  1994-01-15       Impact factor: 4.432

7.  Opioid receptor regulation in mice.

Authors:  B C Yoburn; B Billings; A Duttaroy
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

8.  Tolerance and withdrawal to chronic morphine treatment in the week-old rat pup.

Authors:  G A Barr; S Wang
Journal:  Eur J Pharmacol       Date:  1992-04-29       Impact factor: 4.432

9.  Critical role of the capsaicin-sensitive nerve fibers in the development of the causalgic symptoms produced by transecting some but not all of the nerves innervating the rat tail.

Authors:  Y I Kim; H S Na; J S Han; S K Hong
Journal:  J Neurosci       Date:  1995-06       Impact factor: 6.167

10.  The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.

Authors:  R T Windh; P J Little; C M Kuhn
Journal:  J Pharmacol Exp Ther       Date:  1995-06       Impact factor: 4.030

View more
  5 in total

Review 1.  Long-term impact of neonatal injury in male and female rats: Sex differences, mechanisms and clinical implications.

Authors:  Jamie L LaPrairie; Anne Z Murphy
Journal:  Front Neuroendocrinol       Date:  2010-02-06       Impact factor: 8.606

2.  Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of µ-Opioid Receptor Agonists but Not Prolonged Precipitated Withdrawal in Rats.

Authors:  Lisa R Gerak; Vanessa Minervini; Elizabeth Latham; Saba Ghodrati; Katherine V Lillis; Jessica Wooden; Alex Disney; Stephen M Husbands; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2019-08-22       Impact factor: 4.030

Review 3.  Changing mechanisms of opiate tolerance and withdrawal during early development: animal models of the human experience.

Authors:  Gordon A Barr; Anika McPhie-Lalmansingh; Jessica Perez; Michelle Riley
Journal:  ILAR J       Date:  2011

4.  Zimelidine attenuates the development of tolerance to morphine-induced antinociception.

Authors:  Ercan Ozdemir; Sinan Gursoy; Ihsan Bagcivan; Nedim Durmus; Ahmet Altun
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

5.  Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.

Authors:  Lin-Xin Wu; Yan-Peng Dong; Qian-Mei Zhu; Bo Zhang; Bo-Lun Ai; Tao Yan; Guo-Hua Zhang; Li Sun
Journal:  BMC Cancer       Date:  2021-10-20       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.